Reviva Pharmaceuticals Holdings, Inc. RVPH · Stock Open Reviva Pharmaceuticals Holdings, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Reviva Pharmaceuticals Holdings, Inc. Analysis (RVPH)
Is Reviva Pharmaceuticals Holdings, Inc. a good investment? Reviva Pharmaceuticals Holdings, Inc. (RVPH) is currently trading at 0.4900 USD. Market analysts have a consensus price target of 17.50 USD. This suggests a potential upside from current levels.
Earnings Schedule: Reviva Pharmaceuticals Holdings, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.85.
Investor FAQ
Does Reviva Pharmaceuticals Holdings, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Reviva Pharmaceuticals Holdings, Inc.?
Reviva Pharmaceuticals Holdings, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -1.44.
Company Profile
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
| Split Date | Split Ratio to 1 |
|---|---|
| March 9, 2026 | 1:20 |
Community Discussion